R&D Efficacy

☕ "The Innovation Payoff" This is the ultimate test of a company's 'brainpower.' It measures the actual return on the money spent on R&D. It answers the question: 'For every dollar we spent on new recipes and better machines over the last decade, how much extra annual profit did we actually create?' 📖 The Value Investor's Lens Quality vs. Quantity: Many companies spend billions on R&D just to stay in the same place. High efficacy e.g., >30% means management is making smart, surgical bets that actually grow the business. The Moat Multiplier: A company with high R&D Efficacy is effectively widening its moat at a massive discount compared to competitors who have to spend more to get the same result. 🧮 The Math From the Engine Formula: Growth in Gross Profit / Total R&D Spent during that period × 100 Example: Total R&D spent over 10 years: $1 Billion Annual Gross Profit grew from $500M to $1.5B Growth = $1 Billion Efficacy = 100% Every $1 of R&D created $1 of recurring annual profit. 📊 Benchmarks for "VERY GOOD" Tech/Software: >40% Requires extreme innovation efficiency General Industry: >30% Manufacturing: >35% ⚠️ Watch Out Limitations Delayed Gratification: R&D spending today might take 3-5 years to show up in Gross Profit especially in Pharma. Always look at the 10-year average for the most accurate picture. Negative Efficacy: If Gross Profit is shrinking while R&D is growing, the efficacy will be negative. This is a massive 'Red Flag' suggesting the company's innovation engine is broken. 💡 The Verdict Value investors love companies with high R&D Efficacy because they are the most efficient 'compounding machines' in the market. They don't just spend money; they harvest value.